Validation of an Innovative Neonatal Jaundice Detection System (Picterus) in Indonesia

NCT ID: NCT05630495

Last Updated: 2023-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-12

Study Completion Date

2024-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The long-term goal of this project is to establish Picterus as a permanent tool to detect NNJ in the healthcare services of Indonesia. Offering early detection and therefore, timely treatment to NNJ, will substantially improve neonatal health and directly work towards the Sustainable Development Goal 3.2.2, reduce neonatal mortality. The study as the following specific subgoals:

* Demonstrate that Picterus system performs accurately in Indonesian newborns
* Ensure that Picterus is in line with users' needs in Indonesia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The long-term goal of this project is to establish Picterus as a permanent tool to detect NNJ in the healthcare services of Indonesia. Offering early detection and therefore, timely treatment to NNJ, will substantially improve neonatal health and directly work towards the Sustainable Development Goal 3.2.2, reduce neonatal mortality. The study as the following specific subgoals:

* Demonstrate that Picterus system performs accurately in Indonesian newborns
* Ensure that Picterus is in line with users' needs in Indonesia

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Jaundice, Neonatal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enable high qualitative estimation of bilirubin levels in the blood of new-borns

In this study we aim to collect data of newborns with wider range of bilirubin levels and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns of South-East Asian ethnicity and skin type.

Group Type EXPERIMENTAL

Picterus Jaundice Pro

Intervention Type DEVICE

Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Picterus Jaundice Pro

Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Picterus JP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Infants born with gestational age ≥37 weeks Birth weight ≥2000g and ≤4500g Age 1 - 14 days

Exclusion Criteria

\- Infants transferred to the pediatric ward for advanced treatment. Infants with a skin rash or other disease that affects the skin where measurements are performed.

Infants that receive or have received phototherapy in the last 24 hours. Infants with an inborn disease
Minimum Eligible Age

1 Day

Maximum Eligible Age

14 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Airlangga University

UNKNOWN

Sponsor Role collaborator

RSIA Kendangsaru MERR Surabaya

UNKNOWN

Sponsor Role collaborator

Picterus AS

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anders Aune, MD,MPH

Role: STUDY_DIRECTOR

Picterus AS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitas Airlangga Teaching Hospital

Surabaya, , Indonesia

Site Status RECRUITING

RSIA Kendangsari MERR hospital

Surabaya, , Indonesia

Site Status COMPLETED

Countries

Review the countries where the study has at least one active or historical site.

Indonesia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mahendra TA Sampurna, Dr, SP.A

Role: CONTACT

+62 031-5916290

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mahendra Tri Arif Sampurna, dr., Sp.A(K), PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018/1608Indonesia2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Value of Transcutaneous Bilirubin Devices
NCT06232174 NOT_YET_RECRUITING
NIRS in PDA VLBW Infants
NCT02396004 COMPLETED
Transcutaneous Bilirubinometry and Phototherapy
NCT04246229 NOT_YET_RECRUITING NA
Happy Baby Hearts Study
NCT05842876 COMPLETED